A Cross-sectional Study of Parkinson's Disease and the Prodromal Phase in Community-dwelling Older Adults in Eastern Japan

Overview

Journal Clin Park Relat Disord

Date 2022 Jun 1

PMID 35647516

Authors

Keita Taguchi

Kazuhiro Iwaoka

Takashi Yamaguchi

Ryota Nozaki

Yuriko Sato

Takahiro Terauchi

Yoshio Suzuki

Kai Takahashi

Kenta Takahashi

Hiroshi Akasaka

Naoki Ishizuka

Tetsuya Maeda

Affiliations

Soon will be listed here.

Abstract

Introduction: Parkinson's disease (PD) is more prevalent in the aging population, and epidemiological evidence must be constantly updated to provide an accurate understanding of PD prevalence. Various nonmotor symptoms of PD precede the onset of motor symptoms and prodromal PD. The detection of such symptoms is crucial yet remains challenging. In this study, we aimed to clarify the current prevalence of PD and prodromal PD.

Methods: We enrolled 714 community-dwelling older adults (330 men and 384 women) aged ≥ 65 years (mean age 76.3 years). We used a self-administered questionnaire based on the International Parkinson and Movement Disorder Society prodromal PD criteria to obtain information on prodromes and calculate PD probability. Patients with a probability of ≥ 0.3 were considered as having prodromal PD. We analyzed the crude prevalence rates of PD and prodromal PD.

Results: The crude prevalence rate of PD in our sample was 279.7 per 100,000 persons. The crude prevalence rate of prodromal PD and PD probability were 5034.5 per 100,000 persons and 0.057 ± 0.121, respectively. Never smoker (61.4%), physical inactivity (47.0%), regular pesticide exposure (30.7%), and urinary dysfunction (26.5%) were frequent positive prodromes. Subjects with higher PD probability possessed more variable prodromal markers than those with lower probability.

Conclusion: We examined current prevalence rates of PD and prodromal PD in community-dwelling older adults aged ≥ 65 years in Japan. Our questionnaire-based approach to examine prodromal PD provided valuable evidence for the prevalence of prodromal PD in the aging population.

Citing Articles

Ultrasound evaluation of vagus nerve cross-sectional area in a community-dwelling elderly Japanese cohort.

Oura K, Akasaka H, Ishizuka N, Sato Y, Kudo M, Yamaguchi T PLoS One. 2023; 18(5):e0280661.

PMID: 37200343 PMC: 10194966. DOI: 10.1371/journal.pone.0280661.

References

Chahine L, Weintraub D, Hawkins K, Siderowf A, Eberly S, Oakes D . Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. Mov Disord. 2015; 31(1):86-94. PMC: 4827252. DOI: 10.1002/mds.26373. View

Ross G, Abbott R, Petrovitch H, Tanner C, White L . Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord. 2011; 18 Suppl 1:S199-202. DOI: 10.1016/S1353-8020(11)70062-1. View

Skorvanek M, Martinez-Martin P, Kovacs N, Zezula I, Rodriguez-Violante M, Corvol J . Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism Relat Disord. 2018; 52:83-89. DOI: 10.1016/j.parkreldis.2018.03.027. View

Schenck C, Bundlie S, Mahowald M . Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996; 46(2):388-93. DOI: 10.1212/wnl.46.2.388. View

Ritz B, Ascherio A, Checkoway H, Marder K, Nelson L, Rocca W . Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007; 64(7):990-7. DOI: 10.1001/archneur.64.7.990. View

Chaudhuri K, Healy D, Schapira A . Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006; 5(3):235-45. DOI: 10.1016/S1474-4422(06)70373-8. View

Wirdefeldt K, Adami H, Cole P, Trichopoulos D, Mandel J . Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011; 26 Suppl 1:S1-58. DOI: 10.1007/s10654-011-9581-6. View

Ninomiya T, Nakaji S, Maeda T, Yamada M, Mimura M, Nakashima K . Study design and baseline characteristics of a population-based prospective cohort study of dementia in Japan: the Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD). Environ Health Prev Med. 2020; 25(1):64. PMC: 7603740. DOI: 10.1186/s12199-020-00903-3. View

Espay A, Schwarzschild M, Tanner C, Fernandez H, Simon D, Leverenz J . Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord. 2017; 32(3):319-324. PMC: 5359057. DOI: 10.1002/mds.26913. View

10.

Abbott R, Petrovitch H, White L, Masaki K, Tanner C, Curb J . Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001; 57(3):456-62. DOI: 10.1212/wnl.57.3.456. View

11.

Ravina B, Eidelberg D, Ahlskog J, Albin R, Brooks D, Carbon M . The role of radiotracer imaging in Parkinson disease. Neurology. 2005; 64(2):208-15. DOI: 10.1212/01.WNL.0000149403.14458.7F. View

12.

Espay A, Kalia L, Gan-Or Z, Williams-Gray C, Bedard P, Rowe S . Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. Neurology. 2020; 94(11):481-494. PMC: 7220234. DOI: 10.1212/WNL.0000000000009107. View

13.

Braak H, Del Tredici K, Rub U, de Vos R, Jansen Steur E, Braak E . Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2002; 24(2):197-211. DOI: 10.1016/s0197-4580(02)00065-9. View

14.

Maeda T, Shimo Y, Chiu S, Yamaguchi T, Kashihara K, Tsuboi Y . Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson's disease patients from 35 medical centers. Parkinsonism Relat Disord. 2017; 38:54-60. DOI: 10.1016/j.parkreldis.2017.02.024. View

15.

Watanabe H, Saiki H, Chiu S, Yamaguchi T, Kashihara K, Tsuboi Y . Real-World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J-FIRST. Mov Disord Clin Pract. 2020; 7(4):431-439. PMC: 7197319. DOI: 10.1002/mdc3.12939. View

16.

Ray Dorsey E, Bloem B . The Parkinson Pandemic-A Call to Action. JAMA Neurol. 2017; 75(1):9-10. DOI: 10.1001/jamaneurol.2017.3299. View

17.

Berg D, Postuma R, Adler C, Bloem B, Chan P, Dubois B . MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015; 30(12):1600-11. DOI: 10.1002/mds.26431. View

18.

Liu R, Guo X, Park Y, Huang X, Sinha R, Freedman N . Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol. 2012; 175(11):1200-7. PMC: 3370885. DOI: 10.1093/aje/kwr451. View

19.

Fearnley J, Lees A . Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991; 114 ( Pt 5):2283-301. DOI: 10.1093/brain/114.5.2283. View

20.

Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12):1591-601. DOI: 10.1002/mds.26424. View